Aurobindo Pharma promoters disclose no new encumbrances as of March 31, 2026
Aurobindo Pharma Limited confirmed in a regulatory filing that its promoters have not created any new encumbrances on their shares as of March 31, 2026, aside from those previously disclosed. The declaration, made by K. Nithyananda Reddy on behalf of the promoter group, adheres to SEBI regulations regarding substantial acquisition of shares. The filing details the promoter group's total holding of 30,09,48,721 shares, which constitutes 51.82% of the company's total share capital.
*this image is generated using AI for illustrative purposes only.
Aurobindo Pharma Limited disclosed that its promoters have not created any new encumbrances on their shareholdings as of March 31, 2026, other than those previously reported to the stock exchanges. The declaration, submitted by K. Nithyananda Reddy on behalf of the promoter group, confirms compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. The filing provides a comprehensive breakdown of the shareholding structure within the promoter group, which collectively holds a majority stake in the pharmaceutical company.
The disclosure states that no fresh encumbrances have been made directly or indirectly on the shares held by the promoters during the financial year ended March 31, 2026. This regulatory filing ensures transparency regarding the pledging or hypothecation of shares by key shareholders. The promoter group's total holding stands at 30,09,48,721 shares, accounting for 51.82% of the total share capital of Aurobindo Pharma.
Shareholding Breakdown
The list of promoters and promoter group entities includes individual shareholders and corporate entities. The largest single holding within the group is attributed to RPR Sons Advisors Private Limited and Mrs. P. Suneela Rani, who jointly hold 19,45,61,357 shares, representing 33.50% of the total share capital. Other significant individual shareholders include Mr. Kambam Nityananda Reddy and Mrs. Kirthi Reddy Kambham.
Promoter and Promoter Group Holdings
| Sl. No. | Name | No. of shares held | % of the total share capital |
|---|---|---|---|
| 1 | Mr. Venkata Ramprasad Reddy Penaka | 1,78,33,646 | 3.07 |
| 2 | Mr. Kambam Nityananda Reddy | 2,53,59,572 | 4.37 |
| 3 | Dr. M Sivakumaran | 1,43,57,432 | 2.47 |
| 4 | Mrs. Rajeswari Kambam | 18,08,631 | 0.31 |
| 5 | Mrs. Suneela Rani Penaka | 1,28,799 | 0.02 |
| 6 | Mr. Prasada Reddy Kambham | 2,98,373 | 0.05 |
| 7 | Mr. K Suryaprakash Reddy | 7,380 | 0.00 |
| 8 | Mr. M Sumanth Kumar Reddy | 15,85,214 | 0.27 |
| 9 | Mrs. Kirthi Reddy Kambham | 2,00,62,852 | 3.45 |
| 10 | Mrs. K Spoorthi | 69,39,173 | 1.19 |
| 11 | Mrs. Penaka Neha Reddy | - | 0.00 |
| 12 | Trident Chemphar Limited | 7,82,241 | 0.13 |
| 13 | Axis Clinicals Limited | 6,51,920 | 0.11 |
| 14 | RPR Sons Advisors Private Limited, Mrs. P. Suneela Rani (Jointly Holding) | 19,45,61,357 | 33.50 |
| 15 | Axis Clinicals Limited, Trident Chemphar Limited, RPR Sons Advisors Pvt. Ltd. (Jointly Holding) | 1,65,72,131 | 2.85 |
| Total | 30,09,48,721 | 51.82 |
The document was signed by K. Nithyananda Reddy, an authorised signatory for the promoters and promoter group. The detailed shareholding data was submitted to the National Stock Exchange of India Limited and BSE Limited for their records.
Historical Stock Returns for Aurobindo Pharma
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.23% | +9.59% | +4.58% | +25.67% | +39.18% | +62.07% |
How will the absence of new encumbrances impact investor confidence in Aurobindo Pharma's financial stability?
What strategic initiatives might the promoter group pursue with their current unencumbered majority stake?
Could this clean shareholding structure position Aurobindo Pharma for potential acquisitions or partnerships?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
